FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 18282 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Prostate-specific membrane antigen based diagnostic and therapeutic integration for prostate cancer management. PMID 42437859 · Discov Oncol · 2026-Jul-12 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| YEARS Algorithm for Diagnosis of Suspected Pulmonary Embolism in Patients With Cancer: A Randomized Clinical Trial. PMID 42437322 · JAMA · 2026-Jul-12 The study is a randomized clinical trial in human oncology patients, but it is excluded because it does not meet all required criteria: it lacks a drug-containing intervention and a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). The primary outcome is a composite clinical endpoint (symptomatic VTE or PE-related death) reported as risk differences and proportions, not a time-to-event analysis. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A Longitudinal Disease Progression Model Characterizing Endoscopic Response and Remission in Crohn's Disease. PMID 42436336 · J Pharmacokinet Pharmacodyn · 2026-Jul-11 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Dosimetric analysis of post-radiotherapy sexual dysfunction in patients receiving definitive stereotactic body radiotherapy (SBRT) for prostate cancer: a secondary analysis of MIRAGE. PMID 42435817 · Radiother Oncol · 2026-Jul-11 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Effectiveness of Gross's emotion regulation training on death anxiety in leukemia patients undergoing chemotherapy: a randomized controlled trial. PMID 42432782 · BMC Psychol · 2026-Jul-11 The study is a randomized controlled trial in oncology (leukemia patients) with a drug-containing intervention (chemotherapy), but it is not a Phase III/IIIb or Phase II/III trial, and its primary endpoint is death anxiety (a quality-of-life outcome), not a time-to-event efficacy endpoint such as OS, PFS, DFS, etc. Therefore, it does not meet all criteria for inclusion in the Kaplan-Meier digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of the tree sublingual immunotherapy tablet in the subpopulation of Canadian children with allergic rhinitis and/or conjunctivitis: phase III trial results. PMID 42432760 · Allergy Asthma Clin Immunol · 2026-Jul-11 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Glucagon-like peptide-1 agonists in Parkinson's disease: a meta-analysis. PMID 42432163 · Neurol Sci · 2026-Jul-11 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial. PMID 42259339 · Lancet · 2026-Jul-11 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Single, early intravesical instillation of pirarubicin in the prevention of bladder recurrence after radical nephroureterectomy for upper tract urothelial carcinoma (JCOG1403): a multicentre, open-label, randomised, phase 3 trial. PMID 42435772 · Lancet Oncol · 2026-Jul-10 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 |
H
S
B
|
严格 v3 独有 | excludedsafety_or_economic_primary_endpoint | pending 0 Figure · 0 Panel · risk - |
| Phased rehabilitation nursing improves hip function, reduces complications, and enhances quality of life following total hip arthroplasty: A prospective quasi-experimental cohort study. PMID 42432916 · Medicine (Baltimore) · 2026-Jul-10 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Home-based high-intensity exercise training during neoadjuvant chemotherapy is associated with favorable chemotherapy outcomes and tumor microenvironment remodeling in breast cancer. PMID 42432678 · Cell Commun Signal · 2026-Jul-10 The record describes a randomized trial of exercise (HIIT) during neoadjuvant chemotherapy in breast cancer. While it is an original result report with a drug intervention (neoadjuvant chemotherapy), it fails key eligibility criteria: the trial phase is not stated as Phase III or Phase II/III (it is likely a Phase II or exploratory study), and the primary endpoint is pathological response (Miller-Payne grade), not a time-to-event efficacy endpoint such as OS, PFS, DFS, or any reported Kaplan-Meier/HR analysis. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Ultrahypofractionation of localized prostate cancer-an updated statement of the prostate cancer working group of the German Society of Radiation Oncology (DEGRO). PMID 42432214 · Strahlenther Onkol · 2026-Jul-10 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Adjuvant penpulimab in very-high risk clear cell renal cell carcinoma: a prospective, non-randomized, controlled phase II trial with integrated plasma multi-omics analyses. PMID 42431710 · J Immunother Cancer · 2026-Jul-10 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant Chemotherapy with Trastuzumab with or without Concurrent Radiotherapy in HER2-Positive Locally Advanced Inoperable Breast Cancer- A Phase 2 Randomized Controlled Trial (NEOTRAC STUDY). PMID 42431330 · Int J Radiat Oncol Biol Phys · 2026-Jul-10 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Acute toxicity and quality of life with stereotactic body radiotherapy versus conventional fractionated intensity-modulated radiotherapy to the prostate and pelvis in high-risk prostate cancer (SRAM): A randomized phase II trial. PMID 42431329 · Int J Radiat Oncol Biol Phys · 2026-Jul-10 The trial is a randomized Phase II oncology study in humans, but it fails the eligibility criteria because it is not Phase III/IIIb or a definitive Phase II/III, its primary endpoint is acute toxicity (not a time-to-event efficacy endpoint), and it does not test a drug-containing intervention as the experimental arm. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Brief Report: First-line Chemoimmunotherapy and Chemotherapy Outcomes in Patients with RET Fusion-Positive Lung Cancer in LIBRETTO-431. PMID 42431264 · J Thorac Oncol · 2026-Jul-10 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Evaluating a Tailored Web-Based eHealth Intervention for Symptom Management in Couples Managing Prostate Cancer During the COVID-19 Pandemic: Randomized Clinical Trial. PMID 42430132 · J Med Internet Res · 2026-Jul-10 The study is a randomized trial in prostate cancer patients but evaluates an eHealth intervention (PERC) for symptom management and quality of life. It does not involve a drug-containing intervention and does not have a time-to-event efficacy endpoint (e.g., OS, PFS). Therefore, it is ineligible. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Advanced cholangiocarcinoma in 2025: Therapeutic sequencing and global implementation. PMID 42372729 · Med · 2026-Jul-10 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Tirzepatide monotherapy in Chinese patients with early type 2 diabetes: A randomized, double-blind, placebo-controlled phase 3 trial (SURPASS-CN-MONO). PMID 42296968 · Med · 2026-Jul-10 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Anselamimab in Immunoglobulin Light Chain Amyloidosis: Results From the Randomized CARES Trials. PMID 42212672 · J Clin Oncol · 2026-Jul-10 未发现恶性肿瘤人群证据。 |
B
|
仅广召回影子组 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Addition of Intravesical Recombinant Bacillus Calmette-Guérin to Perioperative Chemoimmunotherapy in Muscle-Invasive Bladder Cancer: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/19. PMID 42212670 · J Clin Oncol · 2026-Jul-10 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant Durvalumab ± Tremelimumab in Combination With Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Muscle-Invasive Bladder Carcinoma: Results of the Phase I/II NEMIO Study. PMID 42190158 · J Clin Oncol · 2026-Jul-10 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Impact of lead-in ADT on grade ≥3 neutropenia in patients with metastatic hormone-sensitive prostate cancer treated with triplet therapy. PMID 42127891 · Med · 2026-Jul-10 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors. PMID 42066233 · J Clin Oncol · 2026-Jul-10 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Real-World Effectiveness, Safety and Quality of Life With Ustekinumab for the Treatment of Crohn's Disease: Results of the UK Ustekinumab Real World Evidence Study (UndieS) Study Group. PMID 42426976 · Aliment Pharmacol Ther · 2026-Jul-09 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Effectiveness and safety of intravitreal faricimab for macular oedema secondary to retinal vein occlusion: a systematic review and meta-analysis. PMID 42426919 · Int J Retina Vitreous · 2026-Jul-09 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Long-term follow-up of a phase 1/2 trial of anti-GDF-15 antibody visugromab plus anti-PD-1 antibody nivolumab in anti-PD-1/-L1 relapsed/refractory solid tumors. PMID 42426863 · J Hematol Oncol · 2026-Jul-09 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Anti-HER2 Therapies in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis. PMID 42426557 · Oncologist · 2026-Jul-09 The record is a systematic review and meta-analysis of multiple clinical trials, not an original report of a single randomized Phase III or Phase II/III trial. Therefore, it is excluded. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Re: Murthy V, Maitre P, Pal M, et al. Bladder Adjuvant Radiotherapy: Phase III Multicenter Randomized Controlled Trial of Adjuvant Radiotherapy or Observation for Postcystectomy Muscle-invasive Bladder Cancer. J Clin Oncol. In press. http://dx.doi.org/10.1200/JCO-25-02093. PMID 42425857 · Eur Urol · 2026-Jul-09 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| A head-to-head comparison of abatacept and adalimumab in adults with early and dual seropositive rheumatoid arthritis plus HLA-DRB1 shared epitope: results from the randomised phase 3 AMPLIFIED trial. PMID 42425800 · Ann Rheum Dis · 2026-Jul-09 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Effects of a fasting-mimicking diet on long-term prognosis in patients with colorectal cancer undergoing radical resection: protocol for a multicentre, prospective, randomised controlled trial. PMID 42425570 · BMJ Open · 2026-Jul-09 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial. PMID 42425122 · Lancet · 2026-Jul-09 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| RecoverEsupport-A Digital Health Intervention for Recovery After Breast Cancer Surgery: Feasibility and Acceptability Outcomes from a Pilot Randomized Controlled Trial. PMID 42424596 · JMIR Form Res · 2026-Jul-09 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Durvalumab Plus Chemotherapy for Advanced Biliary Tract Cancer: A Post Hoc Analysis of the TOPAZ-1 Randomized Clinical Trial. PMID 42424063 · JAMA Oncol · 2026-Jul-09 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Consolidative Thoracic Radiotherapy With Atezolizumab Maintenance in Extensive-Stage Small Cell Lung Cancer: The Phase 2 TREASURE Randomized Clinical Trial (AIO-TRK-0320). PMID 42424047 · JAMA Oncol · 2026-Jul-09 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Secondary Prophylaxis of Recurrent Clostridioides difficile Infections During Systemic Antibiotics with Vancomycin (SPORES-V): study protocol for a randomized controlled trial. PMID 42421140 · Trials · 2026-Jul-09 方案论文未报告临床试验结果。 |
H
|
仅历史库存 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Safety, Tolerability, and Immunogenicity of Revaccination With mRNA-1345 RSV Vaccine Administered 24 Months Following a Primary Dose in Adults ≥60 Years of Age. PMID 42419724 · J Infect Dis · 2026-Jul-09 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Setmelanotide for the Treatment of Acquired Hypothalamic Obesity. PMID 42418774 · N Engl J Med · 2026-Jul-09 This is a Phase III randomized trial of a drug (setmelanotide) for acquired hypothalamic obesity, not a malignant neoplasm. While it meets criteria for being human, randomized, Phase III, drug-intervention, and original-result, it is not oncology. Furthermore, the primary endpoint is mean percent change in BMI, which is not a time-to-event efficacy endpoint. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Phase 3 Trials of Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis. PMID 42149993 · N Engl J Med · 2026-Jul-09 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis. PMID 41812190 · N Engl J Med · 2026-Jul-09 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Comparing the Effectiveness and Safety of Different Third-Line Management Options for Patients with Metastatic Colorectal Cancer: A Systematic Review and Reconstructed Individual Patient Data Meta-Analysis. PMID 42512271 · Cancers (Basel) · 2026-Jul-08 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Perioperative Nivolumab and Ipilimumab with Chemotherapy and Chemoradiation for Resectable Gastric and Gastroesophageal Junction Adenocarcinoma: A Phase 1/2 Non-Randomized Clinical Trial. PMID 42512265 · Cancers (Basel) · 2026-Jul-08 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Immunogenicity and safety of Papilloguard® 4, the first quadrivalent HPV vaccine combined with adjuvant system 04, versus Gardasil® in healthy 15-25-year-old individuals: a phase III, randomized, double-blind, non-inferiority trial. PMID 42424856 · Vaccine · 2026-Jul-08 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Robotic right hemicolectomy with intracorporeal anastomosis versus laparoscopic right hemicolectomy with extracorporeal anastomosis (PRORHEM): protocol for a randomized controlled trial. PMID 42420958 · BMC Surg · 2026-Jul-08 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Rationale, design and methods of the Cul-CM study: a protocol for cultural adaptation of contingency management in adults with stimulant use disorder. PMID 42419893 · BMJ Open · 2026-Jul-08 方案论文未报告临床试验结果。 |
H
|
仅历史库存 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Patterns of presentation and outcomes in stage IV Hodgkin lymphoma: A report from the Children's Oncology Group (COG) AHOD1331 trial. PMID 42419755 · Br J Haematol · 2026-Jul-08 The record is a randomized, drug-interventional trial with a primary time-to-event endpoint (PFS). However, it is a subgroup analysis of the main trial results, and the trial phase is not explicitly stated in the metadata. While it is likely a Phase III trial based on the cooperative group and randomization, the explicit phase cannot be established from the provided text. Therefore, is_eligible is set to null. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Venetoclax in combination with cytarabine with or without idarubicin or azacitidine in children, adolescents, and young adults with relapsed or refractory acute myeloid leukaemia (VENAML): a multicentre, phase 1 expansion study. PMID 42419338 · Lancet Haematol · 2026-Jul-08 The record describes a phase 1 expansion study, not a randomized Phase II/III or Phase III/IIIb trial, and does not report a primary or key secondary time-to-event efficacy endpoint. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of rivaroxaban, colchicine, and famotidine-loratadine with specialist supportive clinical care for fatigue in patients with post-COVID-19 condition in the UK: a multisite, open-label, randomised controlled trial. PMID 42419335 · Lancet Infect Dis · 2026-Jul-08 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy, Safety, and Mechanism of the Qi-Lian-Xiao-Pi Prescription (WW-1) for Chronic Atrophic Gastritis After Helicobacter Pylori Eradication: Protocol for a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. PMID 42418263 · JMIR Res Protoc · 2026-Jul-08 The record is a protocol for an ongoing trial of a traditional Chinese medicine for a precancerous lesion (chronic atrophic gastritis), not a human malignant neoplasm. It lacks a primary/key secondary time-to-event efficacy endpoint and does not report formal results. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy, safety, and dose selection of efepoetin alfa in anemic patients on maintenance dialysis: a phase 2, randomized, multicenter, active-controlled trial. PMID 42415611 · Kidney Res Clin Pract · 2026-Jul-08 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |